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Abbreviations 10 
aaRS aminoacyl-tRNA synthetase 
ABCF1 ATP-binding cassette protein F1 
ACT Artemisinin-based combination therapy 
ATG Autophagy-related protein 
ATrxs Apicoplast thioredoxins 
Clp Caseinolytic protease 
DMT2 Divalent metal transporter 2 
EF-G Elongator factor G 
EF-Tu Elongator factor thermo unstable 
FASII Fatty acid synthesis type II 
GGPP Geranylgeranyl pyrophosphate 
IPP Isopentenyl pyrophosphate 
ISC Iron-Sulfur cluster biosynthesis 
MMV Medicines for Malaria Venture 
  11 
Abstract 12 
Malaria continues to be one of the leading causes of human mortality in the world, and 13 
the therapies available are insufficient for eradication. Malaria is caused by the 14 
apicomplexan parasite Plasmodium. Apicomplexan parasites, including the 15 
Plasmodium spp., are descendants of photosynthetic algae, and therefore they possess 16 
an essential plastid organelle, named the apicoplast. Since humans and animals have no 17 
plastids, the apicoplast is an attractive target for drug development. Indeed, after its 18 
discovery, the apicoplast was found to host the target pathways of some known 19 
antimalarial drugs, which motivated efforts for further research into its biological 20 
functions and biogenesis. Initially, many apicoplast inhibitions were found to result in 21 
“delayed death”, whereby parasite killing is seen only at the end of one invasion-egress 22 
cycle. This slow action is not in line with the current standard for antimalarials, which 23 
seeded scepticism about the potential of compounds targeting apicoplast functions as 24 
good candidates for drug development. However, recent evidence that highlights 25 
apicoplast inhibitors that result in the rapid killing, put this organelle back in the 26 
spotlight. We provide an overview of drugs known to inhibit apicoplast pathways, 27 
alongside recent findings in apicoplast biology that may provide new avenues for drug 28 
development.    29 
 30 
  31 
Introduction 32 
The Apicomplexa, a phylum of protozoan parasites, places a huge burden on global 33 
health and economy. Among these, the human malaria parasite Plasmodium falciparum 34 
is the most impactful. WHO reported that during 2016 there were 216 million malaria 35 
cases and 445,000 deaths globally[1]. Despite intense efforts over the past two centuries 36 
to eradicate malaria, it remains a severe threat to human life. Drug resistance poses one 37 
of the main limitations to the fight against malaria. For example, for decades 38 
chloroquine was the “gold standard” for the treatment of uncomplicated malaria, nearly 39 
halving the death rates among children in Africa[2]. However, drug resistance sabotaged 40 
this success, as shown by the strong link between the emergence of drug resistance and 41 
the resurgence of morbidity and mortality[3]. Nowadays, chloroquine is no longer 42 
appropriate for the treatment of malaria caused by P. falciparum in nearly all 43 
geographic areas. Artemisinin-based combination therapies (ACT) are currently the 44 
frontline antimalarials. Artemisinin is unique in being the only drug that can rapidly 45 
kill every asexual red blood cell stage[4]. However, an increasingly pronounced trend 46 
of delayed clearance time[5] and reports of treatment failure (e.g. [6] and [7]) raise 47 
concerns for the future efficacy of ACT[8]. The introduction of new drugs is a necessity, 48 
and criteria for their activity and specificity based on this history are outlined by leading 49 
programs such as the Medicines for Malaria Venture (MMV)[9]. These include 50 
prioritisation of compounds that result in the fast killing of the parasites. 51 
 52 
Most apicomplexan parasites, including P. falciparum, possess a plastid organelle 53 
called the apicoplast, which is a demonstrated source for drug targets[10–13]. The 54 
apicoplast originated from a secondary endosymbiosis of a red algal cell, and thus it 55 
features some of the essential metabolic pathways that drove that symbiosis[14,15], as 56 
well as a complex multi-compartment structure reflecting its multiple origins[16–18]. The 57 
metabolic roles of the apicoplast in P. falciparum include the biosynthesis of isoprenoid 58 
precursors (IPP), iron-sulfur clusters (ISC), fatty acids (FASII) and haem 59 
intermediates[15,19,20]. Genetics studies have found that these pathways are essential for 60 
different Plasmodium life stages. Specifically, IPP and ISC production are required 61 
during the asexual stages[21,22], while the genes encoding the FASII enzyme fabB and 62 
the haem biosynthesis enzyme ferrochelatase, are only essential during the parasite 63 
liver[23–25] and mosquito[24,25] development stages. The importance of these functions is 64 
further supported by their drug sensitivity (see Fig. 1 for a summary of drugs targeting 65 
apicoplast functions active during P. falciparum asexual development). As an example, 66 
IPP biosynthesis is inhibited by fosmidomycin, which demonstrated effective in vivo 67 
antimalarial activity when conjugated with clindamycin[26,27]. Additionally, ISC 68 
synthesis is affected by D-cycloserine[28], while FASII is inhibited by thiolactomycin, 69 
cerulenin, triclosan, and fops[29]. 70 
Due to these essential synthesis pathways being housed there, apicoplast maintenance 71 
and biogenesis are also essential for parasite survival. Studies describing the importance 72 
of proteins involved in ISC synthesis[22] and of apicoplast proteases[30,31] in Plasmodium 73 
provide examples for this principle. Similarly, studies in the related parasites 74 
Toxoplasma gondii, whose apicoplast shares the same metabolic pathways, highlight 75 
further examples[32–40]. Additionally, due to its complex evolution, different apicoplast 76 
biogenesis pathways are of different evolutionary origins. Thus, in addition to being 77 
essential, many housekeeping processes have their origin in the prokaryotic ancestry of 78 
the algal plastid or were uniquely evolved with the apicoplast acquisition, hence they 79 
have no parallels in humans. These essential and divergent apicoplast biogenesis 80 
pathways are already proven drug targets or have the potential to be exploited for drug 81 
development. We review here the advances made to understand this potential. 82 
Housekeeping pathways hosted in the apicoplast stroma  83 
Many housekeeping pathways hosted in the apicoplast stroma retain a prokaryotic 84 
origin from the algal plastid. Therefore, apicoplast biogenesis is susceptible to the 85 
action of a series of antibiotics. Fluoroquinolones and aminocoumarins typically 86 
interfere with prokaryotic gyrase activity during DNA replication and have proven 87 
antimalarial activity[41,42]. Rifampicin is a selective inhibitor of RNA polymerase and 88 
was also demonstrated to have antimalarial effects both in vitro and in rodent models[43]. 89 
The antiparasitic kinetics of these drugs have been termed “delayed death”[44] because 90 
parasites start dying only after the first round of egress and re-invasion following the 91 
introduction of the drug. 92 
Apicoplast translation provides a rich source for drug and antibiotic targets  93 
Like many Apicomplexa, Plasmodium spp. possess three translationally active 94 
compartments. The cytosol operates eukaryotic translation machinery while the 95 
apicoplast and the mitochondrion have translation systems of prokaryotic origin. Each 96 
system consists of a ribosome, tRNAs, aminoacyl tRNA synthetases (aaRS), initiation 97 
factors and elongation factors. The apicoplast genome encodes the 23S and 16S rRNA, 98 
35 tRNAs, 17 ribosomal proteins and the thermo-unstable translation elongation factor 99 
(EF-Tu)[45]. Other components are encoded in the nuclear genome and imported to the 100 
organelle post-translationally. 15 of the 36 nuclear-encoded aaRSs are exclusively 101 
apicoplast-targeted and four are shared with the cytosol[46,47]. Additionally, the 102 
apicoplast GluRS binds glutamate to both tRNAGlu and tRNAGln, with the latter being 103 
processed by an apicoplast amidotransferase to generate Gln-tRNAGln[48]. Together, 21 104 
aminoacylated tRNAs can form in the apicoplast. The apicoplast prokaryotic-derived 105 
aaRSs are attractive drug targets due to their structural divergence and weak cross-106 
recognition with eukaryotic aaRSs. Common aaRS inhibitors are the amino acid 107 
analogues, which compete with an amino acid in binding to the aaRS catalytic site, 108 
blocking prokaryotic translation. Examples include the isoleucine analogues, 109 
cispentacin and icofungipen; the phenylalanine analogue, ochratoxin A; and the 110 
tryptophan analogues, chaungxinmycin and indolmycin[49] (see Table 1). The inhibitory 111 
power and specificity of indolmycin for the apicoplast TrpRS was recently 112 
demonstrated[50]. Similarly, the isoleucine analogue mupirocin has antiplasmodial 113 
activity due to its inhibition of IleRS. Similarly to indolmycin, mupirocin activity 114 
causes delayed death, which suggests apicoplast inhibition[51].  Further confirmation to 115 
mupirocin specificity is provided by resistant parasites carrying mutations in the 116 
apicoplast IleRS gene[51]. Other inhibitors with antiparasitic activity include the proline 117 
analogue halofuginone[52] and the lysyl-tRNA synthetase inhibitors cladosporin[53], 118 
borrelidin and febrifugine[54]. However, the uncommon immediate, rather than delayed, 119 
effect of these compounds may infer the presence of non-apicoplast targets (see Table 120 
1 for a list of apicoplast-specific aaRS inhibitors). 121 
Apicoplast ribosome 122 
Many of the antibiotics active against Plasmodium inhibit the apicoplast ribosome (See 123 
the enlarged section in Fig. 1 and Table 1). While their mechanisms of action in bacteria 124 
are known, little mechanistic insight is currently available regarding the parasites. 125 
Pactamycin is a translation initiation inhibitor in bacteria that has in vitro 126 
antiplasmodial activity comparable to artemisinin[55]. However, pactamycin is not 127 
likely to be apicoplast-specific since it has a high affinity to P. falciparum cytosolic 128 
ribosome[56]. Tetracycline, macrolides, and lincosamides represent three classes of 129 
antibiotics that are approved for the treatment of several apicomplexan diseases[57] and 130 
that inhibit translation elongation. Tetracyclines bind to multiple sites of the 30S 131 
subunit of the prokaryotic ribosome and inhibit the delivery of aa-tRNAs to the 132 
ribosomal A-site. The insurgence of drug resistance promoted the development of 133 
second (doxycycline) and third (glycylcyclines) generations of compounds[58]. 134 
Doxycycline is an antibiotic commonly used for antimalarial prophylaxis and has a 135 
direct effect on the apicoplast[59]. The tetracycline tigecycline (a glycylcycline) is also 136 
an antiplasmodial. Tigecycline is more effective than its tetracycline predecessors and 137 
a strong candidate for combination with chloroquine[60]. The macrolide azithromycin 138 
and the lincosamide derivative clindamycin were the first antibiotics functionally 139 
characterised to have an antiplasmodial effect by targeting the apicoplast ribosome. 140 
Studies performed in both Toxoplasma[61,62] and Plasmodium[63] showed that resistant 141 
parasites have ribosome mutations mimicking those occurring in resistant bacteria. The 142 
power of macrolides and associated antibiotics for malaria treatment was recently 143 
reviewed in detail[64]. Chloramphenicol is a broad spectrum antibiotic affecting both 144 
Gram-positive and Gram-negative bacteria, docking to the A-site of the ribosome and 145 
stabilising the binding of tRNA to the P-site[65]. Chloramphenicol selectively targets 146 
P. falciparum apicoplast in vitro[66]. Among the few known antibiotics that affect 147 
termination and ribosome recycling in bacteria, fusidic acid was reported to have an in 148 
vitro inhibitory effect on P. falciparum and other Apicomplexa[67–69]. In bacteria, 149 
fusidic acid stabilises the bond between elongation factor-G (EF-G) and the ribosome, 150 
preventing ribosome recycling. Fusidic acid activity on P. falciparum was proposed to 151 
be specific for the apicoplast EF-G, because the mitochondrial EF-G contains a GVG 152 
motif that provids resistance to this drug[67]. Surprisingly, fusidic acid has an immediate 153 
death effect on P. falciparum[70,71], providing evidence for the existence of an off-154 
apicoplast target. IPP supplementation studies (explant in the next section) provided 155 
further support to this hypothesis in P. falciparum[71]. Whether fusidic acid causes 156 
parasite death by targeting the mitochondrial EF-G, by synergically affecting both 157 
apicoplast and mitochondrial EF-G or by blocking the apicoplast EG-F and a yet 158 
unknown third target, remains to be discovered. The antibiotic thiostrepton also 159 
hampers EF-G activity by preventing the docking of this and other factors to the 160 
bacterial ribosome[65]. Thiostrepton is active against P. falciparum but may primarily 161 
target the proteasome with residual activity on apicoplast and mitochondrial 162 
translation[72,73]. 163 
 164 
Table 1 Apicoplast-specific inhibitors of aaRS and ribosome components with details on the parasite 165 
death effect 166 
aaRS inhibitors     
Target PDB GeneID Drug Effect Reference 
isoleucine--tRNA ligase, putative PF3D7_1225100 Mupirocin Delayed death 46,67 
lysine--tRNA ligase, putative PF3D7_1416800 M-33; M-37 Delayed death 68 
tryptophan--tRNA ligase PF3D7_1251700 Indolmycin Delayed death 45 
leucine--tRNA ligase, putative PF3D7_0828200 AN2729 Delayed death 69 
tyrosine--tRNA ligase PF3D7_1117500 TCMDC-141232 Unspecified 70 
glutamate--tRNA ligase PF3D7_1357200 Glu-SA Enzyme inhibition 43 
 
Apicoplast ribosome inhibitors     
Target PDB GeneID Drug Effect Reference 
Small subunit ribosomal RNA PF3D7_API05700 Tetracycline Delayed death Tetracycline 71, 
Doxycycline 54,72 
Tigecycline 55,73 
Large subunit ribosomal RNA PF3D7_API04900 Lincosamides Delayed death Clindamycin 37,57   
Macrolides Delayed death Azithromycin 37,58 
Erythromycin 74 
Clarithromycin 75   
Chloramphenicol Delayed death 61 
Elongation factor G PF3D7_0602400 Fusidic Acid Rapid death* 62 
Elongation factor Tu PF3D7_API02900 Kirromycin, 
GE2270A, 
Amythiamicin A 
Enacyloxin IIa 
Rapid death 62,76 
 
*IPP supplemented P. falciparum proved to be still susceptible to fusidic acid activity[71]. This provides evidence for the 
existence of a second target for this compound, which may putatively be the mitochondrial EF-G[70]. 
 167 
 168 
 169 
Novel apicoplast targets identified and drugs confirmed via IPP supplementation 170 
Yeh and DeRisi demonstrated that IPP biosynthesis is the only required apicoplast 171 
metabolic pathway for culturing P. falciparum asexual stages[21]. In this study, the 172 
authors succeeded to chemically ablate the apicoplast in P. falciparum cultures 173 
supplemented with IPP, obtaining viable IPP-dependant offspring with no plastid[21] 174 
(referred to from here onwards as API-minus). This procedure became a powerful tool 175 
to study apicoplast biogenesis and to characterise organelle-specific drug targets and 176 
compounds (summarised in Fig. 1). In one example, this method allowed the 177 
characterisation of the autophagy-related proteins (ATG) as regulators of apicoplast 178 
vesicle transport[74] and apicoplast segregation[75]. The proteins ATG8 and ATG18 179 
proved to be involved in apicoplast biogenesis in both P. falciparum and T. 180 
gondii[34,76,77], while a similar function for ATG4 was described in T. gondii[78]. These 181 
studies clarified the role of autophagy enzymes in light of the unclear nature of 182 
autophagy in Apicomplexa and highlighted this pathway as a possible target for novel 183 
antimalarials.  184 
IPP supplementation also helped to identify the apicoplast segregation role played by 185 
the caseinolytic proteases ClpC and ClpP[30]. Moreover, the analysis of P. falciparum 186 
dominant negative mutants for the sufC gene revealed apicoplast loss when parasites 187 
were rescued with IPP[22]. The observed apicoplast loss suggests that ISC synthesis 188 
plays a role in organelle biogenesis. This observation calls for a re-evaluation of the 189 
previously suggested exclusive role of ISC synthesis in sustaining the IPP biosynthesis 190 
pathway itself. 191 
Recently, several uncharacterised proteins were assigned apicoplast localization via 192 
proximity-tagging proteomics in P. falciparum and through genetic screens in 193 
P. berghei[79,80]. Among these, the ATP-binding cassette protein ABCF1 and the 194 
membrane transporter DMT2 were described as essential components of P. falciparum 195 
apicoplast, as confirmed by conditional knockdown and IPP rescue of the mutants[79,80]. 196 
These studies provided new important entries to the limited list of currently known 197 
apicoplast proteins and especially apicoplast transporters. 198 
IPP rescue also provided an efficient tool to analyse apicoplast functions in response to 199 
drug exposure. An interesting example is provided by the study of artemisinin-induced 200 
dormancy in P. falciparum[81]. Recrudescence from this dormant stage to complete 201 
recovery occurs only in parasites with a functional apicoplast. Parasites exposed to 202 
fosmidomycin followed by induction of dormancy can also be rescued but only upon 203 
supplementation with either IPP or its derivative geranylgeranyl pyrophosphate 204 
(GGPP). While GGPP can be used to temporarily maintain an API-minus culture, the 205 
recrudescence of dormant API-minus parasites is only achievable by IPP 206 
supplementation[81]. These observations, indicate the possible involvement of IPP in the 207 
recovery mechanism, possibly through influencing mitochondrion activity[81,82]. 208 
In another study, an IPP rescue-based drug screen confirmed that the compound 209 
MMV008138 shows similar kinetics of parasite killing to fosmidomycin and that the 210 
effect is reversible by IPP rescue[83,84]. Further studies identified the enzyme IspD as 211 
the target of MMV008138[85], encouraging the development of new analogues for both 212 
this compound[86] and for the benzoisothiazolones[87]. Although both fosmidomycin and 213 
MMV008138 do not seem to have an effect on gametocytes, parasites lacking an 214 
apicoplast are unable to reach gametocyte maturity unless IPP was supplemented prior 215 
to stage III-IV[88]. This may suggest that while a functional apicoplast is required for 216 
gametocyte survival, these drugs show different pharmacokinetics at this stage. This 217 
limitation was overcome by the development of the MEPicide RCB-185, which affects 218 
both gametocyte and asexual P. falciparum, as confirmed by IPP rescue[89]. Another 219 
IPP based drug-screen identified the membrane metalloprotease, FtsH1, as the target of 220 
the apicoplast biogenesis inhibitor actinonin. Interestingly, as opposed to most other 221 
apicoplast targeting drugs, actinonin has a rapid-death effect on the parasites[31]. A 222 
recent screen, testing the apicoplast-specific effect of multiple antibiotics on API-minus 223 
parasites, provided more support for the immediate death effect of actinonin on 224 
P. falciparum when compared with the effect of other antibiotics[71]. Both studies raise 225 
the possibility that the inhibition of specific apicoplast proteins could generate 226 
apicoplast-defect-dependent rapid parasite death. This hypothesis brings the apicoplast 227 
back to the focus of antimalarial development as a powerful source for targets causing 228 
immediate parasite death. 229 
Sabotaging redox regulation in the apicoplast as a new strategy for drug 230 
development 231 
Redox is the name given to the sum of reducing and oxidizing powers in a compartment. 232 
The carefully maintained balance between oxidising and reducing agents provides a 233 
suitable environment for all cellular functions and is essential for the survival of all 234 
cells. Plasmodium parasites are constantly exposed to signals and molecules causing 235 
changes to their cellular redox balance. For example, during the intraerythrocytic cycle, 236 
the parasites experience oxidative stresses generated exogenously by the host immune 237 
system, and endogenously by the activity of their own mitochondrial metabolism and 238 
from haemoglobin degradation[90,91]. The ability to maintain redox balance is thus a 239 
potential ‘Achilles heel’ for Plasmodium and other Apicomplexa. In support of this, 240 
tipping the parasite redox balance by elevation of exogenous oxidative stress in vitro 241 
results in parasite death for both asexual stages[92] and sexual gametocyte stages[93]. 242 
Moreover, recent evidence suggests that elevation of redox stress in vivo is also 243 
detrimental to the parasites[94]. In this study, which was aimed to evaluate the effect of 244 
animal diet on susceptibility to malaria, elevated oxidation in the liver was identified 245 
as a cause of impaired liver infection[94]. Sabotaging the parasites’ ability to maintain 246 
redox balance is, therefore, emerging as a killing mechanism that could be exploited 247 
for drug development[32]. 248 
In eukaryotic cells, each compartment has its unique redox state, suitable for the 249 
pathways it hosts. Compartmental redox regulatory networks have two arms: (1) 250 
pathways responsible to maintain a redox state that is suited to the biochemical 251 
conditions required in the organelle, e.g. via the action of antioxidants; (2) pathways 252 
that modulate the function of proteins in response to changes in the redox state in a 253 
specific compartment. For example, thioredoxins mediate protein folding, which in turn 254 
affects both their trafficking through compartments and translocation complexes, as 255 
well as their catalytic function. The thioredoxin potential to induce folding is directly 256 
controlled by the redox environment in its corresponding compartment. Due to its 257 
multi-compartmental structure and complex evolutionary origin, the apicoplast is 258 
expected to rely on an elaborate network of redox regulatory pathways[95,96]. This 259 
prediction is based on the different redox conditions found in the origins of the different 260 
apicoplast compartments (e.g. the outermost compartment is likely to be highly 261 
reducing, like the ER; while the PPC is likely less reducing, like the cytosol). This 262 
prediction is further based on the expectation that some apicoplast proteins must be 263 
kept in a state of folding that is suitable for traversing several compartments, and that 264 
all proteins should fold to their catalytic form in their resident compartment. While the 265 
information about these pathways is sparse, evidence points to apicoplast redox 266 
regulation as a promising target for drug development. For example, our recent work 267 
characterized the function of Toxoplasma apicoplast thioredoxins (ATrxs) and 268 
demonstrated their role in apicoplast protein folding and sorting[32]. This study showed 269 
that the deletion of a single redox regulation component is sufficient to cause parasite 270 
death. It further identified ATrx2 as a parasite- and algal-specific protein and generated 271 
an in vitro activity assay that can now be used to screen for inhibitors. Two different 272 
genetic screens[97,98] and our own unpublished data points to the essentiality of ATrx2 273 
also in P. falciparum. ATrx2 is localised in one of the outer apicoplast compartments 274 
(the periplastid compartment[32,99], see Fig 1 for representation). Because of its 275 
localization, inhibitors of ATrx2 need to cross two membranes fewer than inhibitors of 276 
targets in the apicoplast stroma. Likewise, due to its role in organelle biogenesis, ATrx2 277 
inhibitors also have the potential to provide fast killing like actinonin[31] and like a 278 
recently reported putative inhibitor of apicoplast protein translocation[102]. Together 279 
these features highlight ATrx2 as an attractive target for drug development. A 280 
proximity-tagging based analysis[79] has expanded the number of apicoplast proteins 281 
predicted with high-confident in P. falciparum. This allows an evaluation of the number 282 
of potential ATrx substrates and their predicted functions (Table 2). The catalytic 283 
activity of thioredoxins, including ATrxs[32], consists of disulfide exchange with their 284 
substrate, which takes place via a typical double cysteine (CXXC) motif. While target 285 
cysteines on the substrate could be found anywhere, they are commonly located in 286 
CXXC motifs, which can provide a predictive tool in the search for putative substrates. 287 
Table 2 summarizes the proteins found in the proximity tagging screen that also possess 288 
CXXC motifs, and are thus candidate ATrx substrates. CXXC motifs in known 289 
thioredoxin substrates could be found anywhere in the protein sequence where their 290 
reduction or oxidation could affect folding. We would predict that in the case of 291 
apicoplast proteins, CXXC found in the targeting signal are not likely to affect protein 292 
folding once in the organelle and thus those proteins are not included. Further analysis 293 
of these new apicoplast proteins may present new target candidates for drugs inhibiting 294 
apicoplast redox regulation. 295 
  296 
Table 2. Apicoplast-targeted proteins predicted by Boucher et al. (2018)[79] that contain double 297 
cysteines that may serve as ATrx regulation domains  298 
Putative apicoplast proteins containing potential dicysteine domains 
Reference Annotation CxxC domain(s) Essentiality* 
PF3D7_0107700 conserved membrane protein, unknown function CilC Dispensable 
PF3D7_0313800 conserved protein, unknown function CrdC, CpqC Essential 
PF3D7_0313900 conserved protein, unknown function CriC Dispensable 
PF3D7_0414100 conserved membrane protein, unknown function CvkC Dispensable 
PF3D7_0529000 conserved protein, unknown function CnyCC Essential 
PF3D7_0619100 conserved protein, unknown function CilC Essential 
PF3D7_0715200 conserved protein, unknown function CglCC Dispensable 
PF3D7_0721100 conserved protein, unknown function CnlC Essential 
PF3D7_0820600 conserved membrane protein, unknown function CneC, ChtC, CirC Dispensable 
PF3D7_0916200 conserved protein, unknown function CknC Essential 
PF3D7_0918400 conserved protein, unknown function CinC Dispensable 
PF3D7_1023300 conserved protein, unknown function CgtCtaC, CaaC, CtaC Essential 
PF3D7_1242000 conserved protein, unknown function CpaC, CqnC, CknC Essential 
PF3D7_1351800 conserved protein, unknown function CalC, CqyC Essential 
PF3D7_1352000 conserved protein, unknown function CvgC, CkrC Dispensable 
PF3D7_1436100 conserved membrane protein, unknown function CekC Essential 
PF3D7_1437100 conserved protein, unknown function CakC, CpnC Essential 
PF3D7_1457300 conserved protein, unknown function CplC Essential 
Apicoplast proteins with potential redox functions 
Reference Annotation Function Essentiality* 
PF3D7_0529100 thioredoxin-like protein, putative (ATrx2) Redox Essential 
PF3D7_0604700 glyoxalase I (GILP) Glyoxalase System Essential 
PF3D7_0623200 ferredoxin--NADP reductase Redox Essential 
PF3D7_0623500 superoxide dismutase [Fe] (SOD2) Redox Essential 
PF3D7_0716600 cysteine desulfurase Fe-S cluster Essential 
PF3D7_0723700 metallo-hydrolase/oxidoreductase, putative Unknown Essential 
PF3D7_0729200 1-cys peroxiredoxin (AOP) Redox Dispensable 
PF3D7_0815900 dihydrolipoyl dehydrogenase, apicoplast PDC component Dispensable 
PF3D7_0823600 lipoate-protein ligase B Lipoic acid synthesis Dispensable 
PF3D7_0914300 met-10+ like protein, putative Unknown Dispensable 
PF3D7_1020800 dihydrolipoamide acyltransferase component E2 PDC component Essential 
PF3D7_1114800 glycerol-3-phosphate dehydrogenase, putative Carbon metabolism Essential 
PF3D7_1124500 pyruvate dehydrogenase E1 component subunit α PDC component Essential 
PF3D7_1205700 targeted glyoxalase II Glyoxalase system Dispensable 
PF3D7_1212000 glutathione peroxidase-like thioredoxin peroxidase Redox Essential 
PF3D7_1318100 ferredoxin, putative Redox Essential 
PF3D7_1364600 aldehyde reductase, putative reducing enzyme Unknown Essential 
PF3D7_1409100 aldo-keto reductase, putative Unknown Essential 
PF3D7_1419200 thioredoxin-like protein, putative (ATrx1) Redox Dispensable 
PF3D7_1419800 glutathione reductase Redox Essential 
PF3D7_1430700 NADP-specific glutamate dehydrogenase Carbon metabolism Essential 
PF3D7_1437200 ribonucleoside-diphosphate reductase large 
subunit, putative 
DNA replication Essential 
PF3D7_1446400 pyruvate dehydrogenase E1 component subunit β PDC component Dispensable 
PF3D7_1455900 polyprenol reductase, putative Unknown Essential 
 
*The indication of gene essentiality is according to the high-throughput piggyBac transposon mutagenesis screen 
performed by Zhang et al. (2018) on P. falciparum[97]. In this study, libraries of parasite genomes containing a 
single piggyBac insertion were used to identify essential genes by Illumina-based sequencing. This approach 
identified 2042 genes that are dispensable for P. falciparum intraerythrocytic development. 
 299 
Figure 1 Schematic representation of the apicoplast with confirmed and potential drug targets.  300 
The figure represents the various apicoplast compartments delimited by four green membranes. The most 301 
relevant apicoplast functions sustaining Plasmodium spp. intraerythrocytic development are represented. 302 
Antibiotics having a specific effect on the organelle are indicated by names in red. Apicoplast potential drug 303 
targets that have been confirmed by IPP supplementation are depicted in red circles and are placed in their 304 
hypothetical organelle position. The big variety of antibiotics active against the translation machinery are 305 
listed on the right panel, representing an enlargement of the ribosome including the elongation factors EF-G, 306 
EF-Tu and a circle representing the apicoplast tRNA synthetases. 307 
Abbreviations: aaRS: aminacyl-tRNA synthetase; ABCF1: ATP-binding cassette protein F1; ATG8/18: 308 
autophagy related protein 8/18; ATrx1/2: apicoplast-thioredoxin 1/2; ClpC/P: caseinolytic protease C/P; 309 
DMAP: dimethylallyl-pyrophosphate; DMT2: divalent metal transporter 2; DXS: 1-deoxy-D-xylulose 5-310 
phosphate synthase; DXR, 1-deoxy-D-xylulose 5-phosphate reductoisomerase; EF-G: elongation factor-G; EF-311 
Tu: elongation factor thermo unstable; GA3P: glyceraldehyde 3-phosphate; IMC: innermost compartment; 312 
IPP: isopentenyl pyrophosphate; IspD, 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase; IspE, 4-313 
diphosphocytidyl-2-C-methyl-D-erythritol kinase; IspF, 2C-methyl-D-erythritol 2,4-cyclodiphosphate 314 
synthase; IspG, 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase; IspH, 4-hydroxy-3-methylbut-2-315 
enyl diphosphate reductase; PPC: periplastid compartment; OMC: outermost compartment. 316 
 317 
Perspectives  318 
• Malaria continues to be one of the major global killers. Upon its discovery, the 319 
apicoplast was proposed as a prime target for antimalarials. However, the 320 
“delayed death” phenotype, characterized by parasite killing only in the second 321 
generation after the introduction of drugs inhibiting apicoplast targets, does not 322 
align with the killing dynamics proposed for the new generation of 323 
antimalarials. This resulted in scepticism about apicoplast functions providing 324 
good targets for new drugs within the malaria drug research and development 325 
community.  326 
• Several recent studies highlight that there are apicoplast functions whose 327 
inhibition could result in the rapid killing of Plasmodium spp.[31,72,102] and the 328 
related Toxoplasma gondii[100]. Likewise, studies started pointing to potential 329 
apicoplast essential functions in vivo. For example, while IPP complementation 330 
suggests IPP synthesis as the only essential apicoplast function in asexual 331 
stages, experiments point to other crucial apicoplast functions that sustain 332 
parasite growth when fever response is simulated in culture[101]. The same may 333 
well be true for growth under the pressure of oxidative stress generated by the 334 
immune system.  335 
• These observations should provide motivation to deepen our understanding of 336 
apicoplast biology, and our knowledge of the proteins that take part in its 337 
functions. In the context of drug development, it is a high priority to improve 338 
our appreciation of the role of the apicoplast in different parasites life stages in 339 
vivo.   340 
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